FDA approves two supplemental indications for ledipasvir-sofosbuvir in chronic HCV patients

FDA has approved additional indications for ledipasvir–sofosbuvir (Harvoni—Gilead Sciences) for use in chronic hepatitis C virus (HCV) patients with advanced liver disease. Ledipasvir–sofosbuvir in combination with ribavirin for 12 weeks was approved for use in a broader range of patient populations. Specifically, the drug combination was approved for chronic HCV genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis, and for HCV genotype 1-infected patients with decompensated cirrhosis.